XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders’ Equity (Tables)
9 Months Ended
Sep. 30, 2024
Stockholders’ Equity [Line Items]  
Schedule of Fair Value of Options Warrant The fair value of option grants was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:
   Nine Months Ended
September 30,
 
   2024   2023 
Exercise price   $0.7548 to $1.36   $2.59 
Term (years)   5.0    10.0 
Expected stock price volatility   106.65% to 120.00%   105.00%
Risk-free rate of interest   3.75% to 4.02%   4.02%

 

Schedule of Warrant Activity A summary of warrant activity for the nine months ended September 30, 2024 is as follows:
   Number of
Warrants
   Weighted
Average
Exercise
Price
   Total
Intrinsic
Value
   Weighted
Average
Remaining
Contractual Life
(in years)
 
Outstanding as of December 31, 2023   4,213,515   $7.01   $
    4.5 
Issued   3,875,000    1.52    
   —
     
Expired   (323,437)   48.60    
     
Exercised   (2,555,675)   1.64    
     
Outstanding as of September 30, 2024   5,209,403    2.71    
    3.76 
Warrants exercisable as of September 30, 2024   5,209,403   $2.71   $
    3.76 

 

Schedule of Restricted Stock Awards Granted A summary of the Company’s restricted stock awards granted under the equity incentive plans during the nine months ended September 30, 2024 is as follows:
   Number of
Restricted Stock
Awards
   Weighted
Average Grant
Day Fair Value
 
Nonvested on December 31, 2023   1,693    3.16 
Granted   
    
 
Vested   
    
 
Nonvested on September 30, 2024   1,693    3.16 
Schedule of Stock Option Plan A summary of option activity under the Company’s equity incentive plans for the nine months ended September 30, 2024 is presented below:
   Number of
Shares
   Weighted
Average
Exercise
Price
   Total
Intrinsic
Value
   Weighted
Average
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2023   169,362   $26.78   $
    —
    8.4 
Employee options issued   923,000   $1.05    
     
Expired   (2,000)   147.0    
     
Outstanding as of September 30, 2024   1,090,362   $4.78   $
    9.3 
Options vested and exercisable as of September 30, 2024   1,090,362   $4.78   $
    9.3 
Schedule of Stock-Based Compensation Expense Stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 was as follows:
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2024   2023   2024   2023 
Employee stock option awards  $281,388   $182,520   $794,073   $182,520 
Non-employee restricted stock awards   672    2,016    2,002    5,982 
Non-employee stock warrant awards   1,272    5,729    7,661    22,141 
   $283,332   $190,265   $803,736   $210,643 
Schedule of Stock-Based Compensation Expense Included Within Research and Development and General and Administrative Expenses For the three and nine months ended September 30, 2024 and 2023, the amount of stock-based compensation expense included within research and development and general and administrative expenses was as follows:
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2024   2023   2024   2023 
Research and development  $1,272   $5,729   $7,661   $22,141 
General and administrative   282,060    184,536    796,075    188,502 
   $283,332   $190,265   $803,736   $210,643 
Warrant [Member]  
Stockholders’ Equity [Line Items]  
Schedule of Fair Value of Options Warrant The fair value of the January 2023 Existing Warrants on the modification date and the fair value of the April 2024 Inducement Warrants were estimated using the Black-Scholes option-pricing model with the following assumptions:
    March 27,
2024 to
April 1,
2024
 
Exercise price     $1.50 to $5.00  
Term (years)     4.25  
Expected stock price volatility     109.8%  
Risk-free rate of interest     4.18% to 4.34%